Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Limits of the Social Benefit Motive Among High-risk Patients: a Field Experiment on Influenza Vaccination Behaviour

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04230343
Recruitment Status : Completed
First Posted : January 18, 2020
Last Update Posted : January 18, 2020
Sponsor:
Collaborator:
University of Nottingham
Information provided by (Responsible Party):
Burcu Isler, SB Istanbul Education and Research Hospital

Brief Summary:
Influenza vaccine uptake remains low worldwide, inflicting substantial costs to public health and health systems. Messages promoting social welfare have been shown to increase vaccination intentions, and it has been recommended that health professionals communicate the socially beneficial aspects of vaccination. This study aims to provide the first test whether this prosocial vaccination hypothesis applies to the actual vaccination behaviour of high-risk patients by comparing the effects of two motivational messages for promoting vaccination at a tertiary care public hospital in Istanbul, Turkey.

Condition or disease Intervention/treatment Phase
Influenza Vaccine Behavioral Intervention Self-benefit Social-benefit Behavioral: Self-benefit message Behavioral: Other-benefit message Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 244 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Care Provider, Investigator)
Primary Purpose: Prevention
Official Title: Limits of the Social Benefit Motive Among High-risk Patients: a Field Experiment on Influenza
Actual Study Start Date : November 13, 2016
Actual Primary Completion Date : March 25, 2017
Actual Study Completion Date : March 25, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Flu Flu Shot

Arm Intervention/treatment
Experimental: Self-benefit arm Behavioral: Self-benefit message
A pamphlet consisting of a short text and an abstract figure. The top half of the pamphlet described the official criteria for qualifying to be in the risk group. Bottom half indicated that one can gain immunity against influenza by getting the vaccine and included a figure of one smiley face.

Active Comparator: Social-benefit arm Behavioral: Other-benefit message
A pamphlet consisting of a short text and an abstract figure. The top half of the pamphlet described the official criteria for qualifying to be in the risk group. Bottom half indicated that one can gain immunity against influenza by getting the vaccine, and gaining immunity would lower the chances of transmitting the disease to others. The figure included one smiley face surrounded by three other smiley faces.




Primary Outcome Measures :
  1. Vaccine uptake following the introduction of the pamphlet [ Time Frame: On the same day, upto 24 hours ]
    Difference in the number of patients in each arm who agree to receive influenza vaccine following the introduction of the pamphlet. The first half of the pamphlet contains information about the the influenza vaccine and the risk groups who are vulnerable to influenza-associated serious diseases. The second half introduces the self-benefit message. And the final part asks if the participant wants to receive the influenza vaccine now.


Secondary Outcome Measures :
  1. Vaccine uptake in high and low risk group patients following the introduction of the pamphlet [ Time Frame: On the same day, upto 24 hours ]
    Vaccine uptake in high and low risk group patients. The first half of the pamphlet contains information about the the influenza vaccine and the risk groups who are vulnerable to influenza-associated serious diseases. The second half introduces the social-benefit message. And the final part asks if the participant wants to receive the influenza vaccine now.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients hospitalized at medical departments of the hospital who are on the day of discharge

Exclusion Criteria:

  • Egg ellergy
  • Previous allergic reaction to influenza vaccine
  • Pregnancy
  • Cognitive disability

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04230343


Locations
Layout table for location information
Turkey
SB Istanbul Training and Research Hospital
Istanbul, Turkey, 34098
Sponsors and Collaborators
SB Istanbul Education and Research Hospital
University of Nottingham
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Burcu Isler, Principal investigator, SB Istanbul Education and Research Hospital
ClinicalTrials.gov Identifier: NCT04230343    
Other Study ID Numbers: 855 - 21/10/2016
First Posted: January 18, 2020    Key Record Dates
Last Update Posted: January 18, 2020
Last Verified: January 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Influenza, Human
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases